Navigation Links
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Date:5/19/2011

elopment, activity, therapeutic potential and safety of ISIS-TTRRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
4. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
9. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
10. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... DUBLIN , Nov. 27, 2014 ... of the "Global Palmitic Acid Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 The Global Palmitic Acid ... on the current state of the global palmitic acid ... of the industry including definitions, classifications, applications and industry ...
(Date:11/26/2014)... November 26, 2014 Publicis Healthcare Communications ... announced the organization has won a total of 20 ... Health LifeBrands was honored with a Silver Award and ... received eight Awards of Excellence. , The Annual ... advertising and promotion. The Awards provide a forum for ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced ... indicate the company is looking to expand in non-healthcare ... sales.  The healthcare market research firm says that  Siemens ... Kalorama Information,s biennial survey of the IVD market , ... any change in its composition would likely affect IVD ...
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... care consulting firm with offices in Bethesda, MD and Pittsburgh, ... January 2012: , Karen Gerlach, PhD, MPH, to ... Vice President, Program Operations and Over-the-Counter Switch , Mitch ... to President , John Pinney, to Chief Executive Officer ...
... 2012 Aethlon Medical, Inc. (OTCBB: ... devices to address infectious disease, cancer and other ... an Extracorporeal Therapy Scientific Advisory Board to guide ... therapies developed from the Aethlon ADAPT™ system.  Aethlon ...
... Jan. 23, 2012 Novus International Inc., a leading ... and Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced the selection of ... the two companies, strategic collaboration to advance ...
Cached Biology Technology:PinneyAssociates Announces Senior Staff Promotions 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 2First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 3First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 4First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration 5
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... provide statin drugs free of charge so that customers can ... Imperial College London suggest in a new study published this ... in the blood. A wealth of trial data has proven ... attack risk. In a paper published in the Sunday ...
... Mount Sinai School of Medicine, New York, has been ... receive a 2010 ICAAC Young Investigator Award. Sponsored ... an early career scientist for research excellence in microbiology ... postdoctoral training in Molecular Biology at Harvard University in ...
... 250 scientists, engineers, government advisers and groups concerned ... from August 15-20, 2010 to consider the impact ... University of Maryland is co-sponsoring the conference, The ... ), which is co-organized by University of Maryland ...
Cached Biology News:Free statins with fast food could neutralize heart risk, scientists say 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 3
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: